Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

RaPartial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk unilateral clinically localised prostate cancer

Cancer HTA and economic evaluations

PART is a UK‑wide, multi‑centre randomised clinical trial designed to assess whether partial ablation for unilateral intermediate‑risk prostate cancer provides effective oncological outcomes compared with radical treatment, with the added benefit of a reduced side‑effect profile and improved patient‑reported outcomes.

A within‑trial economic evaluation is integrated into the study to estimate the cost‑effectiveness of partial ablation compared with radical treatment from the perspective of the UK NHS, patients and society.

Funders: NIHR HTA

Our Team

Jane Wolstenholme

Associate Professor of Health Economics

Filipa Landeiro

Senior Researcher

Chief Investigator (clinical)

Richard Bryant, Professor of Urology and Academic Director of NDS SITU

Professor of Urology and Academic Director of NDS SITU

Freddie Hamdy, CBE, Nuffield Department of Surgery, University of Oxford.

University of Oxford

Selected publications

Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.

Hamdy FC. et al, (2018), Health Technol Assess, 22, 1 - 96